MTOR and COVID-19: Only a few episodes of acute rejections have been related to a decrease in immunosuppression, suggesting that in the case of COVID-19-related lymphopenia, the temporary cessation of CNI, MPA, or mTOR inhibitors may be safe even for 2 weeks [133].